{"ATC Code":"D04AA32","Abbreviation":"DPH","Aliases":["Benzhydramine","Alledryl","Probedryl","Dihidral","Antistominum","Benzhydraminum","Benzhydroamina","Diphantine","Difenhydramin","Allergical"],"Biological Half-Life":"The elimination half-life ranges from 2.4-9.3 hours in healthy adults. The terminal elimination half-life is prolonged in liver cirrhosis.","Boiling Point":"150-165 °C at 2.00E+00 mm Hg","CAS":"58-73-1","ChEBI":"CHEBI:4636","ChEMBL":"CHEMBL657","ChemicalClasses":[],"Chirality":"achiral","Classes":null,"Color/Form":"Oil","Dosing Info":[{"Method":"Oral","Tiers":{"Common":{"Lower":50,"Upper":150},"Heavy":{"Lower":350,"Upper":600},"Light":{"Lower":15.300000000000004,"Upper":50},"Strong":{"Lower":150,"Upper":350},"Threshold":{"Lower":1,"Upper":15.300000000000004}},"Unit":"mg"}],"Drug Classes":"Breast Feeding; Lactation; Antihistamines","Drug Indication":"Diphenhydramine is a first-generation histamine H1 receptor antagonist (H1 antihistamine) that is widely available as a non-prescription, over-the-counter (OTC) medication. As an OTC medication, diphenhydramine is typically formulated as tablets and creams indicated for use in treating sneezing, runny nose, itchy/watery eyes, itching of nose or throat, insomnia, pruritis, urticaria, insect bites/stings, allergic rashes, and nausea.  Additionally, when the use of oral diphenhydramine is impractical, there are also prescription-only formulations such as diphenhydramine injection products that are effective in adults and pediatric patients (other than premature infants and neonates) for: i) the amelioration of allergic reactions to blood or plasma, in anaphylaxis as an adjunct to epinephrine and other standard measures after acute allergic reaction symptoms have been controlled, and for other uncomplicated allergic conditions of the immediate type when oral therapy is impossible or contraindicated; ii) the active treatment of motion sickness; and iii) use in parkinsonism when oral therapy is impossible or contraindicated, as follows: parkinsonism in the elderly who are unable to tolerate more potent agents; mild cases of parkinsonism in other age groups, and in other cases of parkinsonism in combination with centrally acting anticholinergic agents.","Drug Warnings":"Numerous side effects ... /incl/ drowsiness, confusion, restlessness, nausea, vomiting, diarrhea, blurring of vision, diplopia, difficulty in urination, constipation, nasal stuffiness, vertigo, palpitation, headache, and insomnia. Other side effects observed were urticaria, drug rash, photosensitivity, hemolytic anemia, hypotension, epigastric distress, anaphylactic shock, tightness of the chest and wheezing, thickening of bronchial secretions, dryness of the mouth, nose and throat and tingling, and heaviness and weakness of the hands.","DrugClasses":[],"DurationOfAction":"","EINECS":"200-396-7","EliminationHalfLife":"Range: 2.4–13.5\u0026nbsp;h","European Community (EC) Number":"200-396-7","FDA Pharmacological Classification":"8GTS82S83M","FullSalts":["Diphenhydramine maleate","Diphenhydramine citrate","Diphenhydramine laurylsulfate","Diphenhydramine hydrochloride","Diphenhydramine salicylate"],"HMDB ID":"HMDB0001927","HeavyAtomCount":19,"Human Drugs":"Breast Feeding; Lactation; Antihistamines","IUPACName":"2-benzhydryloxy-N,N-dimethylethanamine","InChI":"InChI=1S/C17H21NO/c1-18(2)13-14-19-17(15-9-5-3-6-10-15)16-11-7-4-8-12-16/h3-12,17H,13-14H2,1-2H3","InChIKey":"ZZVUWRFHKOJYTH-UHFFFAOYSA-N","MeSH Pharmacological Classification":"Drugs used to prevent NAUSEA or VOMITING. (See all compounds classified as Antiemetics.)","Melting Point":"161-162","MolecularFormula":"C\u003csub\u003e17\u003c/sub\u003eH\u003csub\u003e21\u003c/sub\u003eNO","MolecularWeight":"255.35 g/mol","Pharmacodynamics":"Diphenhydramine has anti-histaminic (H1-receptor), anti-emetic, anti-vertigo and sedative and hypnotic properties. The anti-histamine action occurs by blocking the spasmogenic and congestive effects of histamine by competing with histamine for H1 receptor sites on effector cells, preventing but not reversing responses mediated by histamine alone. Such receptor sites may be found in the gut, uterus, large blood vessels, bronchial muscles, and elsewhere. Anti-emetic action is by inhibition at the medullary chemoreceptor trigger zone. Anti-vertigo action is by a central antimuscarinic effect on the vestibular apparatus and the integrative vomiting center and medullary chemoreceptor trigger zone of the midbrain.","Physical Description":"Solid","PrevSalts":["maleate","citrate","laurylsulfate","hydrochloride","salicylate"],"PubChemId":3100,"Record Description":["Diphenhydramine is an ether that is the benzhydryl ether of 2-(dimethylamino)ethanol. It is a H1-receptor antagonist used as a antipruritic and antitussive drug. It has a role as a H1-receptor antagonist, an antiemetic, a sedative, an anti-allergic agent, a muscarinic antagonist, an antiparkinson drug, an antipruritic drug, a local anaesthetic, an antidyskinesia agent, an antitussive and a oneirogen. It is an ether and a tertiary amino compound.","Diphenhydramine - perhaps known most commonly as its brand name formulation Benadryl - is a first-generation H1 receptor antihistamine that is used extensively for the treatment of seasonal allergies, insect bites and stings, and rashes. However, it also has antiemetic, antitussive, hypnotic, and antiparkinson properties. As histamine receptors exist both peripherally and in the central nervous system, diphenhydramine has been shown to cause sedation due to its competitive antagonism of histamine H1 receptors within the central nervous system. While its use in allergy therapy can sometimes fall out of favor due to its sedative effect, diphenhydramine has been repurposed for use within many non-prescription over-the-counter sleep aids and cough-and-cold medications that have been marketed for \"night time\" use.   Diphenhydramine is also used in combination with [DB14132] as the anti-nausea drug [DB00985] where it is utilized primarily for its antagonism of H1 histamine receptors within the vestibular system.  Diphenhydramine has also been shown to be implicated in a number of neurotransmitter systems that affect behaviour including dopamine, norepinephrine, serotonin, acetylcholine, and opioid. As a result, diphenhydramine is being investigated for its anxiolytic and anti-depressant properties.","Diphenhydramine is a Histamine-1 Receptor Antagonist. The mechanism of action of diphenhydramine is as a Histamine H1 Receptor Antagonist.","Diphenhydramine is a first generation antihistamine that is used for symptoms of allergic rhinitis and the common cold. It is also commonly used as a mild sleeping aid. Diphenhydramine has not been linked to instances of clinically apparent acute liver injury.","Diphenhydramine is a first generation antihistamine and ethanolamine with sedative and anti-allergic properties. Diphenhydramine competitively inhibits the histamine-1 (H1) receptor, thereby alleviating the symptoms caused by endogenous histamine on bronchial, capillary and gastrointestinal smooth muscles. This prevents histamine-induced bronchoconstriction, vasodilation, increased capillary permeability, and GI smooth muscle spasms.","DIPHENHYDRAMINE is a small molecule drug with a maximum clinical trial phase of IV (across all indications) that was first approved in 1946 and has 19 approved and 63 investigational indications.","Diphenhydramine is a histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. It has some undesired antimuscarinic and sedative effects. -- Pubchem; Pseudoephedrine is a phenethylamine, and an isomer of ephedrine. Pseudoephedrine is the International Nonproprietary Name (INN) of the (1S,2S)- diastereomer of ephedrine (which has 1R,2S- configuration). Other names are (+)-pseudoephedrine and D-pseudoephedrine (Reynolds, 1989). The enantiomer (-)-(1R,2R)-Pseudoephedrine has fewer side-effects, fewer central nervous system (CNS) stimulatory effects, does not reduce to d-methamphetamine, yet retains its efficacy as a decongestant. However, the patent holder for (-)-Pseudoephedrine (Pfizer/Warner-Lambert) has not yet sought or received government approval for its sale to the public.(US Patent 6,495,529); Treatment for urinary incontinence is an unlabeled use for these medications. Unlabeled use means doctors can use the medication to treat a condition other than that for which it was first approved by the U.S. Food and Drug Administration (FDA). These medications are approved by the FDA for the treatment of nasal congestion caused by colds or allergies. However it has also been successful in treating stress incontinence by increasing the pressure (tension) exerted by the muscles of the bladder neck and the urethra, which helps retain the urine within the bladder. Despite being one of the oldest antihistamines on the market, it is by and large the most effective antihistamine available, either by prescription or over-the-counter, and has been shown to exceed the effectiveness of even the latest prescription drugs. Consequently, it is frequently used when an allergic reaction requires fast, effective reversal of the (often dangerous) effects of a massive histamine release. However, it is not always the drug of choice for treating allergies. Like many other first generation antihistamines, is also a potent anticholinergic agent. This leads to profound drowsiness as a very common side-effect, along with the possibilities of motor impairment (ataxia), dry mouth and throat, flushed skin, rapid or irregular heartbeat (tachycardia), blurred vision at near point due to lack of accommodation (cycloplegia), abnormal sensitivity to bright light (photophobia), pupil dilatation, urinary retention, constipation, difficulty concentrating, short-term memory loss, visual disturbances, hallucinations, confusion, erectile dysfunction, and delirium. -- Wikipedia;.","A histamine H1 antagonist used as an antiemetic, antitussive, for dermatoses and pruritus, for hypersensitivity reactions, as a hypnotic, an antiparkinson, and as an ingredient in common cold preparations. It has some undesired antimuscarinic and sedative effects.","See also: Diphenhydramine Hydrochloride (has salt form); Dimenhydrinate (active moiety of); Diphenhydramine Citrate (has salt form) ... View More ...","Diphenhydramine is an ether that is the benzhydryl ether of 2-(dimethylamino)ethanol. It is a H1-receptor antagonist used as a antipruritic and antitussive drug. It has a role as a H1-receptor antagonist, an antiemetic, a sedative, an anti-allergic agent, a muscarinic antagonist, an antiparkinson drug, an antipruritic drug, a local anaesthetic, an antidyskinesia agent, an antitussive and a oneirogen. It is an ether and a tertiary amino compound.","LiverTox|CNS|Sedative/Hypnotic|Antihistamine"],"References":[{"Name":"Wikipedia","Urls":[{"Link":"https://en.wikipedia.org/wiki/Diphenhydramine","Name":"Diphenhydramine","Sub":false}]},{"Name":"Wikidata","Urls":[{"Link":"https://www.wikidata.org/wiki/Q413486","Name":"Diphenhydramine","Sub":false}]},{"Name":"DrugBank","Urls":[{"Link":"https://go.drugbank.com/drugs/DB01075","Name":"Diphenhydramine","Sub":false}]},{"Name":"PubChem","Urls":[{"Link":"https://pubchem.ncbi.nlm.nih.gov/compound/3100","Name":"Diphenhydramine","Sub":false}]},{"Name":"ChEMBL","Urls":[{"Link":"https://www.ebi.ac.uk/chembl/explore/compound/CHEMBL657","Name":"Diphenhydramine","Sub":false}]},{"Name":"ChEBI","Urls":[{"Link":"https://www.ebi.ac.uk/chebi/searchId.do?chebiId=CHEBI:4636","Name":"Diphenhydramine","Sub":false}]},{"Name":"Common Chemistry","Urls":[{"Link":"https://commonchemistry.cas.org/detail?cas_rn=58-73-1","Name":"Diphenhydramine","Sub":false}]},{"Name":"HMDB","Urls":[{"Link":"https://hmdb.ca/metabolites/HMDB0001927","Name":"Diphenhydramine","Sub":false}]},{"Name":"KEGG","Urls":[{"Link":"https://www.kegg.jp/entry/C06960","Name":"Diphenhydramine","Sub":false}]},{"Name":"UNII","Urls":[{"Link":"https://gsrs.ncats.nih.gov/ginas/app/ui/substances/8GTS82S83M","Name":"Diphenhydramine","Sub":false}]},{"Name":"EPA DSSTox","Urls":[{"Link":"https://comptox.epa.gov/dashboard/chemical/details/DTXSID4022949","Name":"Diphenhydramine","Sub":false}]}],"Reported Fatal Dose":"...PROBABLY BEST DESCRIBED AS LYING NEAR BORDERLINE BETWEEN TOXICITY CLASSES 4 \u0026 5. 4= VERY TOXIC: PROBABLE ORAL LETHAL DOSE (HUMAN) 50-500 MG/KG, BETWEEN 1 TEASPOON \u0026 1 OZ FOR 70 KG PERSON (150 LB). 5= EXTREMELY TOXIC: PROBABLE ORAL LETHAL DOSE (HUMAN) 5-50 MG/KG, BETWEEN 7 DROPS \u0026 1 TEASPOONFUL. /HYDROCHLORIDE/","SMILES":"CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2","Salts":["maleate","citrate","laurylsulfate","hydrochloride","salicylate"],"SaltsAcidCount":[1,0,0,1,1],"SaltsAmineCount":[1,1,1,1,1],"SaltsUNII":["54A11R7E1Y","4OD433S209","3E2CN035LB","TC2D6JAD40","707L3YC54L"],"Scheduling":[{"gov":"Canada","schedule":"OTC substance"},{"gov":"United Kingdom","schedule":"P substance"},{"gov":"United States","schedule":"OTC substance"},{"gov":"United Nations","schedule":"Unscheduled substance"}],"Solubility":"In water, 3.06X10+3 mg/L at 37 °C","Stability/Shelf Life":"Slowly darkens on exposure to light. Stable under ordinary conditions /Diphenhydramine hydrochloride/","StoreUNII":["8GTS82S83M"],"StructureBase64":"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","Subjective Effects":null,"Therapeutic Uses":"Anesthetics, Local; Anti-Allergic Agents; Antiemetics; Histamine H1 Antagonists; Hypnotics and Sedatives","Title":"Diphenhydramine","UNII":"8GTS82S83M","Wikidata":"Q413486","Wikipedia":"Diphenhydramine","XLogP":3.3}